Prot #CDFV890G12101: A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients with Myeloid Diseases

Project: Research project

Project Details

StatusActive
Effective start/end date9/19/22 → 6/1/29

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CDFV890G12101)